Michael Barry

51 results

The cost of biosimilars is usually less than half that of the originator products.

Hospitals are being offered a €500 incentive for every patient they move off two expensive high-tech medicines and on to cheaper alternatives, in the (...)

Lauren  Whelan (15) from Loreto Crumlin in Dublin has SMA with Spinraza activists protesting outside Leinster House in Dublin in September 2018. File photograph: Garrett White/Collins Photo Agency

Health authorities in England and Wales have approved the use of the drug Spinraza, leaving Ireland, with Estonia, as the only EU states barring acces(...)

In many cases, the National Centre for Pharmacoeconomics  rules that new drugs are  not value for money at the initial price sought by the pharma company. Photograph: Alan Betson

The Government and pharmaceutical companies need to fundamentally reform the approach to setting medicine prices, a spokesman for the major drug compa(...)

The cost to the State of replicating the move could be as high as €500 million over five years, estimates Prof Michael Barry, clinical director of the National Centre for Pharmacoeconomics. Photograph: PA Wire

It could cost the State up to €500 million to provide public patients with wider access to innovative new cancer therapies in the same way health insu(...)

VHI will provide wider access to cancer drugs, including Pembrolizumab, for stage three melanoma, and Pertuzumab (Perjeta) for patients with early stage breast cancer. Photograph: iStock

Commercial rivals to the VHI say they have no plans to follow the semi-State health insurer’s lead by providing wider access to cancer drugs for some (...)

Liberian nurses carry the body of an Ebola victim in 2014. Vaccines were not available to victims of the epidemic, lobby group Access to Medicines Ireland says. Photograph: Ahmed Jallanzo/EPA

Spiralling drug costs threaten to bankrupt healthcare systems and deny patients access to essential medicines, according to lobby group Access to Medi(...)

Drugs developed  by major pharma companies, including Pfizer, Amgen, AstraZeneca and Johnson & Johnson’s Actellion business, are among those that have now secured approval. File photo. Photograph: Simon Dawson/Bloomberg

Ten new medicines approved for use by the Health Service Executive last week have been waiting for more than two years on average for sanction, accord(...)

Sam Bailey from Rathcoole, Co Dublin, his father Paul, mother Fiona and sisters Kayla and Sarah, protesting  over the HSE’s decision not funding the drug Spinraza, outside the Dáil on Thursday. Photograph: James Forde

Access to medicines is always an emotive issue. If you’re a patient with a life-limiting condition, you’ll never understand why you cannot access a dr(...)

Pharmaceutical companies have rejected allegations that they are pursuing “predatory pricing” for new medicines. Photograph:  Getty Images

Pharmaceutical companies have rejected allegations that they are pursuing “predatory pricing” for new medicines. The Irish Pharmaceutical Healthcare (...)

Minister for Health Simon Harris has asked the Medicines Management Programme to look at putting measures in place to expand access to Pembro. Photograph: Gareth Chaney/Collins

Women with cervical cancer will get access to a potentially life-saving drug under new plans being brought forward by the Minister for Health. “Pemb(...)

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next
  • Last »